IRVINE, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, announced today that the Company has successfully completed the enrollment of a total of 1,551 patients across two identical Phase III Clinical Trials of its anti-allergy medication PreHistin(R) in patients with moderate to moderately severe seasonal allergic rhinitis. The trials are being conducted at 23 sites across the central, southern and eastern United States.
